title: Antimicrobial susceptibility among Neisseria gonorrhoeae in New Zealand in 2002.
abstract: OBJECTIVE
  To estimate the prevalence of antimicrobial resistance among Neisseria gonorrhoeae, and to determine whether the increase in ciprofloxacin resistance observed in Auckland in 2001 had occurred in other parts of the country.
  
  
  METHODS
  The antimicrobial susceptibility of N. gonorrhoeae (isolated in New Zealand over a 4-month period between April and August 2002) was tested at either LabPlus, Auckland District Health Board, or at ESR, using the same agar dilution method.
  
  
  RESULTS
  The prevalence of resistance to the antimicrobials tested was: ceftriaxone, 0%; ciprofloxacin, 6.8%; penicillin, 9.0%; spectinomycin, 0%; and tetracycline, 27.8%. There were few statistically significant geographical differences in resistance within New Zealand. Gonococcal infections acquired in Asia were more likely to be ciprofloxacin and penicillin resistant than infections acquired in New Zealand.
  
  
  CONCLUSIONS
  Ciprofloxacin resistance among N. gonorrhoeae in New Zealand has reached a level where this antibiotic is no longer the most appropriate first-line treatment. In fact, ceftriaxone should now be considered the most reliable option for the treatment and control of gonorrhoea in New Zealand, particularly in the Northland/Auckland region.
authors.affiliation: LabPlus, Auckland District Health Board, New Zealand. helen.heffernan@esr.cri.nz
authors.forename: Helen
authors.initials: H
authors.lastname: Heffernan
authors.forename: Mike
authors.initials: M
authors.lastname: Brokenshire
authors.forename: Rosemary
authors.initials: R
authors.lastname: Woodhouse
authors.forename: Anne
authors.initials: A
authors.lastname: MacCarthy
authors.forename: Tim
authors.initials: T
authors.lastname: Blackmore
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001208:Asia / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D002939:Ciprofloxacin / Q000494:pharmacology / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology*; D006801:Humans; D007223:Infant; D008297:Male; D008826:Microbial Sensitivity Tests / Q000706:statistics & numerical data; D008875:Middle Aged; D009344:Neisseria gonorrhoeae / Q000187:drug effects* / Q000302:isolation & purification; D009520:New Zealand / Q000453:epidemiology; D010406:Penicillins / Q000494:pharmacology / Q000627:therapeutic use; D015995:Prevalence; D017678:Sex Distribution; D000198:Spectinomycin / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D010406:Penicillins; D002939:Ciprofloxacin; D000198:Spectinomycin